期刊文献+

尼妥珠单抗联合调强放疗及周期化疗治疗局部晚期宫颈癌的临床观察 被引量:15

Clinical Observation of Nimotuzumab Combined with Intensity Modulated Radiation Therapy(IMRT) and Cycles of Chemotherapy for Locally Advanced Cervical Cancer
下载PDF
导出
摘要 目的探讨尼妥珠单抗联合调强放疗及周期化疗在局部晚期宫颈癌的治疗中的临床效果。方法将80例局部晚期宫颈癌患者分为对照组和观察组。观察组患者43例,行尼妥珠单抗联合调强放疗及周期化疗治疗;对照组患者37例,行调强放疗及周期化疗。比较2组患者的临床有效率、肿瘤体积退缩情况、不良反应发生率以及局部复发和远处转移。结果在放疗结束后3个月,宫颈癌患者治疗的总有效率观察组和对照组分别为88.4%和70.3%,观察组显著高于对照组(P<0.05);在治疗后2周,观察组患者的肿瘤体积显著小于对照组(P<0.05);在治疗后4周,2组患者肿瘤体积存在显著统计学差异(P<0.05)。2组患者在治疗后1年内均有远处转移和局部复发情况发生,其中观察组患者的局部复发和远处转移发生情况显著低于对照组(P<0.05)。2组患者不良反应发生情况不存在统计学差异(P>0.05)。结论尼妥珠单抗联合调强放疗及周期化疗能够显著提高局部晚期宫颈癌患者的近期疗效,快速退缩肿瘤体积,降低患者的复发率和远处转移率。 Objective To study the clinical efficacy of nimotuzumab combined with intensity modulated radiation therapy ( IMRT) and cycles of chemotherapy for locally advanced cervical cancer .Methods 80 patients with locally advanced cervical cancer,were divided into the control group and the observation group;43 patients in the observation group received nimotuzumab combined with IMRT and cycles of chemotherapy ,37 patients in the control group received IMRT and cycles of chemotherapy . Clinical efficiency ,tumor size shrinking situation ,the incidence of adverse reactions ,local recurrence and distant metastasis of the 2 groups were compared .Results 3 months after radiotherapy , the total effective rate of the observation group and the control group patients were 88.4%and 70.3%,respectively,the observation group was significantly higher than the control group (P〈0.05);2 weeks after treatment ,tumor size of the observation group was significantly smaller than the control group ( P〈0.05);4 weeks after treatment ,there had no significant difference in tumor size between the 2 groups ( P〉0.05);Within 1 year after treatment,both groups had distant metastasis and local recurrence ,and distant metastasis and local recurrence of the observation group were significantly lower than the control group ( P〈0.05);Adverse reactions between the 2 groups had no significant difference (P〉0.05).Conclusion Nimotuzumab combined with IMRT and cycles of chemotherapy can significantly improve short-term curative effect of locally advanced cervical cancer ,quickly reduce tumor volume ,recurrence and distant metastasis .
出处 《实用癌症杂志》 2017年第3期461-463,共3页 The Practical Journal of Cancer
关键词 调强放疗 宫颈癌 尼妥珠单抗 周期化疗 Intensity-modulated radiation therapy ( IMRT) Cervical cancer Nimotuzumab Cycles of chemotherapy
  • 相关文献

参考文献8

二级参考文献78

  • 1王树森,管忠震,向燕群,汪波,林桐榆,姜文奇,张力,张惠忠,侯景辉.鼻咽癌组织中EGFR和p-ERK蛋白表达的检测及意义[J].中华肿瘤杂志,2006,28(1):28-31. 被引量:46
  • 2黄晓东,易俊林,高黎,徐国镇,金晶,杨伟志,卢泰祥,吴少雄,吴仁瑞,胡伟汉,谢伟长,韩非,高远红,高剑铭,潘建基,陈传本,朗锦义,李涛,董昱,付玉彬,樊林,李柏森,黎静,王晓怀,陈炳旭,高献书,张萍,吴湘玮,胡炳强.抗表皮生长因子受体单克隆抗体h—R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究[J].中华肿瘤杂志,2007,29(3):197-201. 被引量:99
  • 3胡巧英,刘鹏,王磊,付真富.Ⅲ、Ⅳ a期鼻咽癌患者放疗同期化疗加辅助化疗的疗效[J].癌症,2007,26(4):394-397. 被引量:43
  • 4吴仁瑞,吴少雄,赵充,谢方云,高剑铭,胡伟汉,高远红,李凤岩,崔甜甜,卢泰祥.h-R3联合放疗治疗局部晚期鼻咽癌的Ⅱ期临床研究[J].癌症,2007,26(8):874-879. 被引量:24
  • 5Crombet-Ramos T, Rak J, Perez R, et al. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3 : a humanized anti-EGFR antibody [J]. Int J Cancer, 2002,101(6) :567-575.
  • 6Boland W K, Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity [J]. Expert Opin Biol Ther, 2009,9 (9):1199- 1206.
  • 7Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients [J]. J Clin Oncol, 2004,22(9):1646- 1654.
  • 8Diaz Miqueli A, Blanco R, Garcia B, et al. Biological activity in vitro of anti- epidermal growth factor receptor monoclonal antibodies with different affinities [J]. Uybridoma (Larchmt), 2007,26 ( 6 ) : 423-431.
  • 9Diaz Miqueli A, Rolff J, Lemm M, et al. Radiosensitisation of U87 MG brain tumors by anti-epidermal growth factor receptor monoclonal antibodies [J]. Br J Cancer, 2009,100(6) :950-958.
  • 10Ramakrishnan M S, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin [J]. nabs, 2009,1 ( 1 ) : 41-48.

共引文献130

同被引文献154

引证文献15

二级引证文献97

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部